Matthew Barcus
Stock Analyst at Chardan Capital
(2.88)
# 1,778
Out of 4,761 analysts
23
Total ratings
21.74%
Success rate
19.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $14 → $12 | $1.40 | +757.14% | 2 | Nov 8, 2024 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $12.84 | +110.28% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.93 | +652.69% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $21.27 | +50.45% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $3.17 | +6,840.06% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.08 | +192.21% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $9.52 | -15.97% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $80 → $60 | $1.24 | +4,738.71% | 3 | Nov 17, 2022 |
Zura Bio
Nov 8, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $1.40
Upside: +757.14%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $12.84
Upside: +110.28%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.93
Upside: +652.69%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $21.27
Upside: +50.45%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $3.17
Upside: +6,840.06%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.08
Upside: +192.21%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $9.52
Upside: -15.97%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $80 → $60
Current: $1.24
Upside: +4,738.71%